Literature DB >> 31368220

Emicizumab and thrombosis: The story so far.

Michael Makris1,2, Alfonso Iorio3, Peter J Lenting4.   

Abstract

Entities:  

Year:  2019        PMID： 31368220     DOI： 10.1111/jth.14556

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  13 in total

1.  Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban.

Authors:  Armando Tripodi; Veena Chantarangkul; Lidia Padovan; Marigrazia Clerici; Erica Scalambrino; Flora Peyvandi
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

2.  Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor.

Authors:  Charles R Lefèvre; Anaïs Jaffré; Adeline Pontis; Fabienne Nedelec-Gac; Pierre Guéret; Isabelle Gouin-Thibault; Bernard Fraisse; Sophie Bayart; Benoit Guillet
Journal:  TH Open       Date:  2021-05-12

Review 3.  Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

Review 4.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 5.  Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal:  Thromb Haemost       Date:  2020-07-27       Impact factor: 5.249

6.  Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE).

Authors:  Carmen Escuriola Ettingshausen; Robert F Sidonio
Journal:  Ther Adv Hematol       Date:  2021-09-23

Review 7.  Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia.

Authors:  Midori Shima
Journal:  Res Pract Thromb Haemost       Date:  2020-04-28

Review 8.  Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.

Authors:  Sandra Le Quellec
Journal:  Drug Des Devel Ther       Date:  2020-02-03       Impact factor: 4.162

9.  The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me.

Authors:  Simon Fletcher; Kathryn Jenner; Michael Holland; Kate Khair
Journal:  Health Expect       Date:  2021-12-08       Impact factor: 3.377

Review 10.  Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century.

Authors:  Valder R Arruda; Bhavya S Doshi
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 3.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.